Blocking the b7-h4 pathway with novel recombinant antibodies enhances t cell-mediated antitumor responses

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Dangaj, Denarda ^a   Scholler, Nathalie ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b SRI INTERNATIONAL   (United States)

Author keywords

B7 H4; Cell surface expression; Immunotherapy; Ovarian cancer; Recombinant antibodies; Targeting

Indexed keywords

RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL SURFACE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; IMMUNE RESPONSE; IMMUNOBLOTTING; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MOLECULAR PATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; SIGNAL TRANSDUCTION; SURVIVAL RATE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT;

EID: 84885760228     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25913     Document Type: Article

References (10)

1. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203- 13; PMID:12529460; http://dx.doi.org/10.1056/ NEJMoa020177
2. Torres MP, Ponnusamy MP, Lakshmanan I, Batra SK. Immunopathogenesis of ovarian cancer. Minerva Med 2009; 100:385-400; PMID:19910891
3. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G, Zou W. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007; 67:8900-5; PMID:17875732; http://dx.doi. org/10.1158/0008-5472.CAN-07-1866
4. Wei J, Loke P, Zang X, Allison JP. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J Exp Med 2011; 208:1683- 94; PMID:21727190; http://dx.doi.org/10.1084/ jem.20100639
5. Cheng L, Jiang J, Gao R, Wei S, Nan F, Li S, Kong B. B7-H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer 2009; 19:1481- 6; PMID:19955922; http://dx.doi.org/10.1111/ IGC.0b013e3181ad0fa2
6. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203:871-81; PMID:16606666; http://dx.doi.org/10.1084/jem.20050930
7. Dangaj D, Lanitis E, Zhao A, Joshi S, Cheng Y, Sandaltzopoulos R, Ra HJ, Danet-Desnoyers G, Powell DJ Jr., Scholler N. Novel recombinant human B7-H4 antibodies overcome tumoral immune escape to potentiate T cell anti-tumor responses. Cancer Res 2013; Forthcoming; PMID:23722540; http:// dx.doi.org/10.1158/0008-5472.CAN-12-3457
8. Chen C, Qu QX, Shen Y, Mu CY, Zhu YB, Zhang XG, Huang JA. Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape. Cancer Lett 2012; 317:99-105; PMID:22108530; http://dx.doi.org/10.1016/j.canlet.2011.11.017
9. Zhang L, Wu H, Lu D, Li G, Sun C, Song H, Li J, Zhai T, Huang L, Hou C, et al. The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene 2013; Forthcoming; PMID:23318460; http://dx.doi.org/10.1038/onc.2012.600
10. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi. org/10.1056/NEJMoa1302369